AngioChem to Present New ANG1005 Clinical Data at AACR

MONTREAL--(Business Wire)--
AngioChem, a biotechnology company discovering and developing drugs that are
uniquely capable of crossing the blood-brain barrier, today announced that it
will present updated data from clinical studies of ANG1005 at the Annual Meeting
of the American Association for Cancer Research (AACR), being held April 18-22,
2009 in Colorado. The data to be presented relate to the potential safety,
efficacy and utility of ANG1005 in primary and secondary brain cancers.

ANG1005 is a novel taxane derivative created from the Engineered Peptide
Compound (EPiC) platform that is designed to cross the blood-brain barrier (BBB)
by receptor-mediated transcytosis, overcoming the BBB`s normal function of
blocking foreign substances which prevents more than 95 percent of all drugs
from reaching the brain.

The schedule of poster presentations for ANG1005 is as follows:

Abstract Title: ANG1005 as a promising new drug therapy for patients with malignant glioma
Poster Session: Experimental and Molecular Therapeutics 26
Number: 3781
Date/Time: Tuesday, April 21, 2009, 8:00 AM Local Time
Location: Hall B-F, Poster Section 38

Abstract Title: ANG1005: Development of a new chemical entity for the treatment of advanced solid tumors and brain
metastases
Poster Session: Experimental and Molecular Therapeutics 26
Number: 3782
Date/Time: Tuesday, April 21, 2009, 8:00 AM Local Time
Location: Hall B-F, Poster Section 38

Abstracts and information about the AACR and its Annual Meeting may be found at
www.aacr.org.

About ANG1005

ANG1005 is a novel taxane Engineered Peptide Compound (EPiC) that is designed to
cross the BBB. Studies have shown that ANG1005 gains entry into the brain
compartment by targeting the low-density lipoprotein receptor-related protein
(LRP) which is one of the most highly expressed receptors on the surface of the
BBB. Once inside the brain, ANG1005 enters tumor cells using the same
receptor-mediated pathway through LRP, which is upregulated in various cancer
cells including malignant glioma and metastatic cancers in the brain.

ANG1005 is currently being evaluated in two separate Phase 1/2 multicenter,
open-label, dose escalation studies to explore the maximum tolerated dose and
obtain data on safety, tolerability and preliminary evidence of efficacy in
patients with recurrent malignant glioma, and in patients with advanced solid
tumors and brain metastases. For recurrent malignant gliomas and metastatic
brain cancer, treatment options for patients are limited and prognoses are
dismal.

Data to date from the Phase 1/2 studies of ANG1005 in patients with primary and
secondary brain cancers demonstrated that ANG1005 has an excellent safety and
tolerability profile, as evidenced by laboratory and neurocognitive data, and
does not show evidence of eliciting an immune response in humans.

About AngioChem

AngioChem is a clinical-stage biotechnology company discovering and developing
new breakthrough drugs that are uniquely capable of crossing the blood-brain
barrier to treat brain diseases. These new Engineered Peptide Compounds
(EPiC)have the potential to address significant medical needs, many of which
cannot be effectively addressed due to the fundamental physiological challenge
the blood-brain barrier presents for therapeutic intervention. AngioChem`s lead
product candidate, ANG1005, is in two separate Phase 1/2 clinical studies in
patients with primary brain cancers and in cancer metastases. Additionally,
AngioChem is developing a deep and broad product pipeline, including small and
large molecules, for the treatment of a wide range of brain diseases and related
disorders, including brain cancer, cancer metastases, neurodegenerative and
metabolic diseases. Founded in 2006, AngioChem maintains headquarters in
Montreal, Canada. For additional information about the Company, please visit
http://www.angiochem.com.

Yates Public Relations
Kathryn Morris, 845-635-9828

Copyright Business Wire 2009